GT Biopharma (GTBP) Operating Expenses (2010 - 2026)

GT Biopharma (GTBP) has reported Operating Expenses for 17 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Operating Expenses rose 307.17% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 147.11% increase from a year earlier, with the FY2025 full-year figure at $6.8 million, up 49.93% from the prior year.
• Operating Expenses was $2.0 million for Q1 2026 at GT Biopharma, down from $3.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $7.0 million in Q3 2022 and troughed at -$645000.0 in Q4 2024.
• A 5-year average of $2.8 million and a median of $3.0 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 120.36% in 2024 and surged 670.85% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $5.8 million in 2022, then tumbled by 45.17% to $3.2 million in 2023, then slumped by 120.36% to -$645000.0 in 2024, then surged by 670.85% to $3.7 million in 2025, then slumped by 46.03% to $2.0 million in 2026.
• The last three Operating Expenses figures came in at $2.0 million (Q1 2026), $3.7 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.